Kinetics of glyburide metabolism by hepatic and placental microsomes of human and baboon

Biochemical Pharmacology

Volumn 73, Issue 12, 2007, Pages 2012-2019

  Zharikova, Olga L ^a   Ravindran, Selvan ^a   Nanovskaya, Tatiana N ^a   Hill, Ronald A ^b   Hankins, Gary D V ^a   Ahmed, Mahmoud S ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

Baboon liver; Baboon placenta; Drug metabolism; Enzyme kinetics; Glyburide (glibenclamide) metabolism; Human liver; Human placenta; Microsomal enzymes; Pregnancy

Indexed keywords

2 HYDROXYCYCLOHEXYLGLYBURIDE; 3 HYDROXYCYCLOHEXYLGLYBURIDE; 4 HYDROXYCYCLOHEXYLGLYBURIDE; CYTOCHROME P450; DRUG METABOLITE; ETHYLHYDROXYGLYBURIDE; GLIBENCLAMIDE; ISOENZYME; PROTEIN M2; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BABOON; CATALYSIS; CELL ACTIVITY; DRUG HYDROXYLATION; DRUG METABOLISM; FEMALE; HUMAN; LIVER MICROSOME; METABOLITE; MICROSOME; NONHUMAN; PLACENTA; PRIORITY JOURNAL;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; ISOENZYMES; KINETICS; MICROSOMES; MICROSOMES, LIVER; MOLECULAR STRUCTURE; PAPIO; PLACENTA; PREGNANCY; SPECIES SPECIFICITY;

EID: 34247557546     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.03.005     Document Type: Article

References (27)

1. Langer O. Oral hypoglycemic agents and the pregnant diabetic: from bench to bedside. Semin Perinatol 26 (2002) 215-224
2. Langer O., Conway D.L., Bercus M.D., Xenakis E.M., and Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 343 (2000) 1134-1138
3. Anderson G.D. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 44 (2005) 989-1008
4. Nanovskaya T.N., Nekhayeva I., Hankins G.D., and Ahmed M.S. Effect of human serum albumin on transplacental transfer of glyburide. Biochem Pharmacol 72 (2006) 632-639
5. Ravindran S., Zharikova O.L., Hill R.A., Nanovskaya T.N., Hankins G.D., and Ahmed M.S. Identification of glyburide metabolites formed by hepatic and placental microsomes of humans and baboons. Biochem Pharmacol 72 (2006) 1730-1737
6. Hakkola J., Pelkonen O., Pasanen M., and Raunio H. Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: role in intrauterine toxicity. Crit Rev Toxicol 28 (1998) 35-72
7. Houston M.L. The development of the baboon (Papio sp) placenta during the fetal period of gestation. Am J Anat 126 (1969) 17-30
8. Stokes W.S. Spontaneous diabetes mellitus in a baboon (Papio cynocephalus anubis). Lab Anim Sci 36 (1986) 529-533
9. Boffelli D., McAuliffe J., Ovcharenko D., Lewis K.D., Ovcharenko I., Pachter L., et al. Phylogenetic shadowing of primate sequences to find functional regions of the human genome. Science 299 (2003) 1391-1394
10. 14C in man. Arzneimittelforschung 19 (1969) 1428-1434 [German]
11. Fuccella L.M., Tamassia V., and Valzelli G. Metabolism and kinetics of the hypoglycemic agent glipizide in man-comparison with glibenclamide. J Clin Pharmacol 13 (1973) 68-75
12. Balant L., Fabre J., and Zahnd G.R. Comparison of the pharmacokinetics of glipizide and glibenclamide in man. Eur J Clin Phamacol 8 (1975) 63-69
13. Rydberg T., Wǻhlin-Boll E., and Melander A. Determination of glibenclamide and its two major metabolites in human serum and urine by column liquid chromatography. J Chromatgr 564 (1991) 223-233
14. Rydberg T., Jönsson A., and Melander A. Comparison of the kinetics of glyburide and its active metabolites in humans. J Clin Pharm Ther 20 (1995) 283-295
15. Fischer V., Rodríguez-Gascón A., Heitz F., Tynes R., Hauck C., Cohen D., et al. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab Dispos 26 (1998) 802-811
16. Zhang H., Henion J., Yang Y., and Spooner N. Application of atmospheric pressure ionization time-of-flight mass spectrometry coupled with liquid chromatography for the characterization of in vitro drug metabolites. Anal Chem 72 (2000) 3342-3348
17. n analyses to the characterization of novel glyburide metabolites formed in vitro. J Chromatogr A 794 (1998) 15-25
18. Rydberg T., Jönsson A., Karisson M.O., and Melander A. Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 43 (1997) 373-381
19. Jönsson A., Hallengren B., Rydberg T., and Melander A. Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes. Diabetes Obes Metab 3 (2001) 403-409
20. Jönsson A., Rydberg T., Sterner G., and Melander A. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol 53 (1998) 429-435
21. Brian W.R. Hypoglycemic agents. In: Levy R.H., Thummel K.E., Trager W.F., Hansten P.D., and Eichelbaum M. (Eds). Metabolic drug interactions (2000), Lippincott Williams & Wilkins, Philadelphia 529-543
22. Van Giersbergen P.L., Treiber A., Clozel M., Bodin F., and Dingemanse J. In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clin Pharmacol Ther 71 (2002) 253-262
23. Naritomi Y., Terashita S., and Kagayama A. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. Xenobiotica 34 (2004) 415-427
24. Hill R.A., Rudra S., Peng B., Roane D.S., Bounds J.K., Zhang Y., et al. Hydroxyl-substituted sulfonylureas as potent inhibitors of specific [3H] glyburide binding to rat brain synaptosomes. Bioorg Med Chem 11 (2003) 2099-2113
25. Nanovskaya T.N., Deshmukh S.V., Nekhayeva I.A., Zharikova O.L., Hankins G.D., and Ahmed M.S. Methadone metabolism by human placenta. Biochem Pharmacol 68 (2004) 583-591
26. Dahl-Puustinen M.L., Alm C., Bertilsson L., Christenson I., Östman J., Thunberg E., et al. Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytion hydroxylation phenotypes. Br J Clin Pharmacol 30 (1990) 476-480
27. Glogner P., and Heni N. Hydroxylierung von Glibenclamid durch leberpunktionszylinder. Arzneimittelforschung 25 (1975) 860-861